Systems Oncology Approach to Optimize Ovarian Cancer Treatment
NCT ID: NCT06117384
Last Updated: 2023-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2022-01-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer
NCT02973750
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
NCT05574673
Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
NCT04752865
Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO
NCT06917469
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00429793
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biomolecular profiling
Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Available tumor tissue/blood samples
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helsinki University Central Hospital
OTHER
University of Helsinki
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anniina Färkkilä
Assistant Professor, Specialist in Gynecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anniina Färkkilä, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Helsinki University Central Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University and Helsinki University Hospital
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUS33342021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.